Non-steroidal anti-inflammatory drugs (NSAIDs) are among the world's most 2 frequently prescribed medications for arthritic and inflammatory conditions, but their use 3 increases the risk of upper-gastrointestinal (UGI) toxicity. The effects range from mild UGI 4 symptoms (e.g. dyspepsia) to severe complications, such as peptic ulcers and UGI 5 haemorrhage, perforation or pyloric obstruction, which sometimes result in hospital admission 6 and death. The incidence of these serious UGI adverse events is approximately 1.5% -2.0% 7 per year of therapy [1] [2] [3] , four times higher than in nonusers 4, 5 . 8
Several evidenced-based guidelines have been proposed to reduce the burden of UGI 9 events attributable to NSAID use [6] [7] [8] [9] [10] . Preventive strategies in particular include: 1) 10 substituting COX (cyclooxygenase)-2-selective inhibitors (coxibs) for a non-selective 11 (ns)NSAID; and 2) combining an NSAID with so-called gastroprotective agents (GPAs), 12 including proton-pump inhibitors (PPIs), histamine-2 receptor antagonists (H 2 RAs), and 13 misoprostol, a synthetic E1 prostaglandin analog [6] [7] [8] [9] [10] [11] [12] [13] . 14 The first method involves prescribing a coxib instead of an nsNSAID. The 15 gastrointestinal toxicity caused by nsNSAIDs is mainly due to inhibition of COX-1 isoform 16 14 . Coxibs were developed to improve the UGI safety profile by preferentially inhibiting the 17 inducible COX-2 isoform of the COX enzyme, which is involved in the desired anti-18 inflammatory effect. Although coxibs have been shown to be as effective as nsNSAIDs for 19 relieving pain and do reduce the risk of UGI complications [15] [16] [17] [18] , cardiovascular toxicity 20 emerged unexpectedly during their post-marketing studies 17, [19] [20] [21] . This led to the voluntary 21 withdrawal of two coxibs: rofecoxib in September 2004 and valdecoxib in April 2005 22 . 22
The second preventive method advocated in NSAID users is co-prescription of GPAs 23 as they have been proven to reduce the incidence of NSAID-induced ulcer complications 3, 12, 24 23 . 25 advanced age, a medical history of UGI events, serious co-morbidity, and concurrent 4 administration of anticoagulants and corticosteroids as considerable risk factors [6] [7] [8] [9] . The 5 guidelines are less consistent with regard to some other possible risk factors, such as high 6 doses or the use of multiple NSAIDs [7] [8] [9] , infection with Helicobacter pylori 8, 9 , or concurrent 7 use of selective serotonin reuptake inhibitors (SSRIs) 7, 9 . 8
Though the need for preventive strategies is recognized, correct adherence to this 9 guidelines-supported advice remains low in daily clinical practice: a review showed that most 10 patients (76%) with one or more risk factors had not been assigned a recommended 11 preventive strategy 24 . This is presumed to be the major explanation for the observation that, 12 even though the prevalence of H. pylori is steadily decreasing in Western countries, the 13 incidence of peptic ulcer complications has not changed over the past 20 years 25 . Other 14 studies have reported a tendency of prescribing preventive strategies to patients at low risk 15 (up to 66%) [26] [27] [28] [29] . Although extensive data are available on the use of preventive strategies in 16 NSAID users, little is known on how the prescription of these strategies was influenced by the 17 by time (calendar year) and the withdrawal of rofecoxib. 18 The implementation of future guidelines would be improved by better insight into 1) 19 the adherence of general practitioners to the guidelines, and 2) how time and rofecoxib 20 withdrawal influenced the prescription behaviour of preventive strategies by general 21 practitioners. To examine time trends in and predictors of preventive strategies in day-to-day 22 practice among older NSAID users, we performed a population-based cohort-study, using 23 data from a Dutch general practitioner database between 1996 and 2006. We also studied the 24 possible influence of time and rofecoxib withdrawal on the observed trends. 25 
Patients and Methods 1

Study design 3
A dynamic cohort study was conducted among incident NSAID users aged ≥ 50 years. 4 5
Source of data 6
The data used were contained in the Integrated Primary Care Information (IPCI) 7 database, which is a dynamic general practitioner research database containing the 8 longitudinal computer-based medical records of currently 1.2 million patients in the 9
Netherlands. The IPCI database was set up in 1992, since when it has greatly expanded. The 10 IPCI population has the same gender and age distribution as the Dutch general population 30 . 11
In the Dutch health care system, all citizens are registered at a GP practice, which acts 12 as a gatekeeper in a two-way exchange of information with secondary care. The medical 13 record of each individual patient can therefore be assumed to contain all relevant medical 14 information. To further ensure completeness of the data, participating GPs are not allowed to 15 use additional paper-based medical records. 16 Data held within the database comprise not only demographics, symptoms, and 17 diagnoses (using the International Classification for Primary Care (ICPC 31 ) and free text), but 18 also referrals, clinical and laboratory findings, and hospitalizations. Information on drug 19 prescriptions comprises their official label text, quantity, strength, ICPC coded indication, 20 prescribed daily dose, and the Anatomical Therapeutic Chemical (ATC 32 ) classification code. 21
The IPCI database complies with European Union guidelines on the use of medical 22 data for medical research and has been proven valid for pharmaco-epidemiological research. 23
Extensive details on the database have been reported elsewhere 33 We defined a preventive strategy as: 1) the use of a coxib, or 2) co-prescription of 9
GPAs (H 2 RA, PPI, or misoprostol; either co-prescribed or the fixed combination with 10 diclofenac) within two days of the index NSAID to proxy preventive use. This proxy has been 11
shown to have a positive predictive value of approximately 85-90% in the IPCI database 34 . 12
The primary outcomes of interest were correct prescription, over-prescription, or 13 under-prescription of preventive strategies at the index date. Correct prescription was defined 14 as use of a preventive strategy in high-risk NSAID users and no use in low-risk patients. 15
Under-prescription was defined as the absence of a preventive strategy in high-risk NSAID 16 users. Over-prescription was defined as the presence of a preventive strategy in low-risk 17 NSAID users. In line with evidence from randomized controlled trials, we considered co-18 prescription of a PPI with a coxib in high-risk users as correct prescription 35, 36 . 19
To avoid doubts about the need of preventive strategies in groups at the edge of the 20 definitions we also performed a sub-group analysis using only patients at high or very high 21 risk of NSAID-related UGI complications. Patients with at least one risk factor were defined 22 as high-risk NSAID users, whereas NSAID users at very high risk comprised persons ≥ 75 23 years or with a prior history of UGI complications. A further subgroup analysis was made in 24 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w Results 
1
Study cohort 2
Within the source population of 154,518 people aged 50 years and over, we identified 3 55,962 incident NSAID users without any of the exclusion criteria. Of these, 5,836 used 4
GPAs in the six months prior and were excluded. In total, 50,126 patients were included in 5 the cohort. The median age of the study population was 63.1 (SD: 10.7) years; 56.9% was 6 female. Baseline characteristics are described in table 1. 7 Twenty-six different types of NSAIDs were prescribed, diclofenac accounting for the highest 8 number of prescriptions (38.8%), followed by ibuprofen (16.8 %) and naproxen (15.7%). 9
Risk factors in NSAID users 11 Table 1 shows that 28,441 patients (56.7% of the study population) had no NSAID-12 related UGI risk factor and were therefore defined as low-risk NSAID users. Individuals with 13 at least one risk factor (43.3%) were defined as high-risk NSAID users; 81.6% of them had 14 one risk factor and 18.4% had two or more risk factors. Age above 65 years was the most 15 frequent (39.7%) of the NSAID-related UGI risk factors, followed by concomitant use of 16 anticoagulants (8.6%), and diabetes mellitus as co-morbid condition (7.5%). 17
Diabetes mellitus and heart failure were more prevalent among high-risk users than 18 among low-risk users (p-value<0.001). A high NSAID dose was rare, but significantly more 19 prevalent among low-risk users than among high-risk users (2.4% vs 1.7%, p<0.001). 20
Preventive strategies 22
In total, 11.3% of all NSAID users received a preventive strategy in the form of a 23 GPA. Excluding Arthrotec, PPIs were the most common co-prescribed GPAs (77.1%), 24 Of all high-risk patients, those with a history of UGI complications (OR 4.0; 95% CI 9 2.9-5.4) or who concomitantly used systemic steroids (OR 3.7; 95% CI 2.5-5.6) had the 10 highest chance of being prescribed a preventive strategy (Table 2A ). Despite some guidelines 11 identifying diabetes mellitus, heart failure, high NSAID dose, or the use of SSRI as a risk 12 factor for NSAID-related UGI complications, these risk factors did not increase the odds of 13 receiving preventive strategies. The odds of receiving a preventive strategy increased with the 14 number of NSAID prescriptions on the same day (data not shown), and over calendar time 15 (Table 2B ). The likelihood of receiving a preventive strategy was highest for prescriptions of 16 indometacin (OR 3.1; 95% CI 1.9-5.2) and ketoprofen (OR 2.5; 95% CI 1.2-5.5) and the 17 lowest for carbasalate calcium (OR 0.3; 95% CI 0.1-0.8) (Table 2B) . 18 
19
Correct, over-and under-prescription of preventive strategies in NSAID users 20
Risk set 1 21 Figure 1 shows the time trend in prescription of preventive strategies in the 50, 126 Figure 2C ). 9
Influence of rofecoxib withdrawal on preventive strategies in high risk users 11
In our study population, the use of coxibs increased from the time of their introduction 12 patients at high risk (at least one risk factor), under-prescription increased significantly after 22 rofecoxib withdrawal (from 56.6% before to 60.1% after rofecoxib withdrawal, p=0.04), but it 23 returned to period 1 levels quite rapidly again in period 3 (from 56.6% before to 58.0% two 24 year after rofecoxib withdrawal, p=0.56). Correct prescription decreased (from 43.0% to 25 withdrawal (from 50.4% before to 50.1% after rofecoxib withdrawal, p=0.9). This shows that 3 the main effect was seen in patients at moderate risk (at least one risk factor but no UGI 4 complication and age<75). Indeed, under-presciption increased significantly in this subgroup 5 from 61.1% in study period 1 to 66.6% in study period 2 (p=0.01). 6 NSAID users with at least one UGI risk factor and 52% of patients with a medical history of 8 UGI events was not prescribed a proper preventive strategy. Over-prescription of preventive 9 drugs was low, but rose from 3% in 1996 to 12% in 2006. 10
Our findings are in line with other Dutch studies reporting under-prescription of 11 preventive strategies in patients who would benefit from appropriate protection at a range of 12
43%-87%
33, 36-40 . Consistently low rates of prescription of preventive strategies have also 13 been reported in studies from other countries 28, [42] [43] [44] [45] . In a recent pooled analysis of 11 studies 14 related to the appropriate use of gastroprotective strategies in NSAID users, 76% of patients 15 at high risk did not receive a preventive strategy 24 . Our analysis extended these data in the 16 sense that we demonstrated that that figure depends largely on the time of measurement, 17 because we had data available of eleven subsequent calendar years. 18
Over-prescription of preventive strategies was low in our study-population: it has been 19 reported in the range of 12-33% 27, 28, 46, 47 . However, other studies did not study over-20 prescription over time and in such a big study population. 21
As for our secondary aim, we showed that the withdrawal of rofecoxib may have had 22 an effect on appropriate use of prophylactic strategies in moderate high-risk patients. 23
Immediately after the withdrawal of rofecoxib we saw a significant increase in under-24 prescription in patients with a risk factor for NSAID related UGI complications, especially 25 F o r P e e r R e v i e w 16 when we excluded persons at very high risk. However, this effect disappeared quickly and no 1 causality between the date of rofecoxib withdrawal and the small increase in under-2 prescription can be attributed. This finding however, is in line with another Dutch study 3 describing the effects of rofecoxib withdrawal where the authors showed that 34% of patients 4 who stopped coxib therapy were switched to an nsNSAID without a PPI, whereas only 21% 5 were switched to an nsNSAID with a co-prescription of a PPI 48 . 6
Some methodological aspects of this study make that our results should be interpreted 7
carefully. First, because we used prescription data instead of more reliable proxies for drug 8 use, we were unable to study actual drug utilization. Secondly, although it has been clearly 9 demonstrated that only high-dose H 2 RAs reduce the endoscopic ulcer rates associated with 10 NSAIDs, we defined every H 2 RA prescription, irrespective of dose, as a preventive strategy. 11
Thirdly, we did not have any information about over-the-counter-use of NSAIDs. Some 12 H 2 RAs, such as ranitidine, were available over-the-counter as well. While these 13 considerations are important, the aim of the study was to determine whether general 14 practitioners' prescription of a preventive strategy to NSAID users reflected an intention to 15 comply with (inter)national guidelines. Because we have considered single H2RA dose as a 16 preventive strategy, we underestimated under-prescription of preventive strategies. 17
The strength of the present study is that, through ICPC-codes and free text, the IPCI-18 database contains complete information on all UGI risk factors and on drug prescriptions, 19 including their quantity, strength, and prescribed daily dose. Because it contains a large 20 number of eligible subjects and reflects the Dutch general population, the database also 21 minimizes the potential for bias. Furthermore, we study the influence of calendar year on 22 prescription of GPAs among NSAID users. We also address issues of over-prescription, 23 which have not been studied before over time and in such a big study population. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 An additional finding of note is that physicians are not aware of the need for 1 gastroprotective strategies when prescribing carbasalate calcium or acetylsalicylacid, as the 2 likelihood of receiving a preventive strategy was lowest in patients using this type of 3 medication. 4
In conclusion, we observed that physicians increase correct prescriptions of 5 gastroprotection over a decade, which may be the result of guidelines, education, and 6 probably the availability of generic PPIs. Despite the improvement, prescription of 7 recommended strategies was still unacceptably low in 2006, especially in vulnerable 8
populations. Non-adherence to gastroprotective measures lead to increased risk of NSAID-9 associated complications such as UGI-bleeds, as we have shown before 49 . The withdrawal of 10 rofecoxib may had have a temporarily negative effect on gastroprotection, especially in the 11 patients at risk but below age of 75 and without a history of UGI complications. This 12
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We would also like to thank the reviewers for their welcome advice and useful comments. We hope our reply and adjustments as specified below in a point by point fashion are satisfactory. The comments are in bold and our answers are in italic. Where appropriate, we incorporated reviewers' suggestions in our manuscript. 3. Figure 2 should be labeled "very-high risk cohort" rather than "high-risk cohort."
Answer: we have adjusted this in the title of Figure 2 .
I assume that the data in the high-risk cohort are comparable. This should be analyzed and stated. 
Prescription of preventive strategies in high risk cohort
Correct prescription Under prescription 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Figure 1 and 2, we demonstrate this time effect. To better explain this time trend we revised the manuscript and added calendar year as a predictor in Table 2 . Table 2 shows that calendar year is a major predictor of prescription of preventive strategies in high-risk patients.
2) Prescription of preventive strategies in very high risk cohort (age>75 yrs or UGI bleeding/ulceration), similar to Figure 2 in the manuscript
2) Determination of over-prescription in low-risk users
Most studies only focused on under-prescription in high-risk patients [5] [6] [7] [8] 10 . Because we also included low-risk NSAID users in our population, we are able to focus not only on correct and under-prescription, but also on over-prescription. Over-prescription has been studied before 9, [13] [14] [15] , but only in small study cohorts over short time-spans. Data on over-prescription are clinically relevant, indicating that general practitioners are prescribing gastroprotection to NSAID users, regardless of identified UGI risk factors. As is shown in Figure 1 , overprescriptions did increase over time. [16] [17] [18] or to evaluate changes in patients characteristics 19 .
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